Centre cracks down on misuse of weight-loss GLP-1 drugs

The Central government has intensified action against the misuse and unauthorised sale of weight-loss and diabetes drugs, particularly GLP-1 receptor agonists, amid rising concerns over their unchecked availability. The move comes as demand for these drugs surges across India, with authorities warning of serious health risks linked to unsupervised consumption.

Nationwide inspections and regulatory action

The Drug Controller General of India, along with State Drug Controllers, has conducted inspections across 49 entities, including online pharmacies, wholesalers, retailers and weight-loss clinics. Authorities have issued notices for violations and warned that non-compliance could lead to licence cancellations, financial penalties and legal proceedings. The crackdown targets both physical and digital supply chains enabling easy access to such drugs.

Rising demand and unchecked accessibility

GLP-1 drugs, widely used for treating type 2 diabetes and obesity, are witnessing a sharp increase in demand. However, regulators have flagged concerns over their availability without valid prescriptions through retail outlets and online platforms. The growing presence of cheaper generic variants has further increased accessibility, raising questions about quality control and responsible usage.

Medical risks and strict prescription norms

The government has reiterated that these medicines cannot be sold over the counter and must only be prescribed by qualified specialists such as endocrinologists and internal medicine experts. GLP-1 drugs function by regulating insulin, reducing appetite and slowing gastric emptying. However, misuse can lead to side effects ranging from nausea and dizziness to severe complications such as pancreatitis, kidney injury and thyroid cancer.

Important Facts for Exams

• GLP-1 receptor agonists are used in treating type 2 diabetes and obesity.
• They work by enhancing insulin secretion and reducing appetite.
• The Drug Controller General of India regulates drug approval and safety in India.
• Non-communicable diseases like obesity and diabetes are major public health challenges in India.

Advertising curbs and public advisory

To prevent misuse, the government has directed manufacturers to stop promotional advertisements encouraging non-prescription use. Officials have emphasised that improper sale, misleading promotion or unauthorised prescriptions will attract strict penal action. Citizens have been urged to use such medications only under medical supervision and obtain them through authorised channels, while continuing to prioritise lifestyle changes such as balanced diet and regular exercise.